Cancer Research and Treatment

Original Articles

Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant NSCLC: Dong Kwon Kim, Jin Woo Park, Hyeon Bin Cho, Su Jin Choi, Sung Sook Lee, YeongMun Kim, Jii Bum Lee, Sun Min Lim, Mi Ra Yu, Byoung Chul Cho; Received December 23, 2025 Accepted March 18, 2026 Published online March 31, 2026; DOI: https://doi.org/10.4143/crt.2025.1399 [Accepted]

Abstract PDF: Purpose
Third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKIs) improved outcomes in EGFR-mutant non-small cell lung cancer (NSCLC); however, the subsequent development of resistance emphasizes the necessity of overcoming this therapeutic limitation. MET amplification is one of the major resistance mechanism in EGFR-mutant NSCLC, bypassing EGFR inhibition by activating cell survival, proliferation, and metastasis. Combining MET- and EGFR-TKIs is thus emerging as a promising therapeutic strategy to overcome resistance to EGFR TKIs.
Materials and Methods
This study aimed to investigate the combination of the selective MET TKI vabametkib and a third-generation EGFR TKI lazertinib in MET-amplified EGFR TKI resistance models. Inhibition of downstream signaling and cell proliferation by vabametkib plus lazertinib were evaluated in osimertinib-resistance NSCLC cell lines (HCC827-AR) and patient-derived organoid (YUO-010) by western blot and Cell Titer-Glo assay.
Results
In vitro studies demonstrated that vabametkib plus lazertinib synergistically inhibited EGFR/MET phosphorylation, leading to markedly enhanced anti-proliferative effects through downstream PI3K/AKT and MAPK pathway blockade. To investigate the antitumor effects in in vivo, we employed two patient-derived xenograft (PDX) models (YHIM-1035(1) and YHIM-1053) harboring MET amplification, as characterized by whole-exome sequencing or droplet digital PCR (ddPCR). Consistent with the in vitro findings, treatment with vabametkib plus lazertinib produced pronounced suppression of tumor growth in both models through a synergistic mechanism.
Conclusion
These findings establish vabametkib plus lazertinib as a promising strategy for MET-amplified NSCLC, currently under evaluation in an ongoing phase II clinical trial (NCT05541822).

588 View
64 Download

Safety and Efficacy of Combining Metastasis-Directed Stereotactic Ablative Radiation Therapy with Tyrosine Kinase Inhibitors Versus Immune Checkpoint Inhibitors in Metastatic Hepatocellular Carcinoma: Eunyeong Yang, Jeong Il Yu, Hee Chul Park, Myung Ji Goh, Byeong Geun Song, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Moon Seok Choi, Jung Yong Hong, Minsuk Kwon, Nalee Kim; Received September 5, 2025 Accepted February 1, 2026 Published online February 3, 2026; DOI: https://doi.org/10.4143/crt.2025.966 [Accepted]

Abstract PDF: Purpose
Immune checkpoint inhibitors (ICIs) have become a standard therapy for metastatic hepatocellular carcinoma (HCC), often as an alternative to tyrosine kinase inhibitors (TKIs). However, safety data combining ICIs with stereotactic ablative radiotherapy (SABR) remain limited. We compared the safety and efficacy of SABR combined with ICIs versus TKIs in patients with extrahepatic metastatic HCC.
Materials and methods
This single-center retrospective study included patients with HCC who received SABR for extrahepatic metastases combined with either TKIs or ICIs within 30 days of SABR between January 2010 and June 2024. Adverse events (AEs; CTCAE v5.0) and oncologic outcomes were evaluated using logistic regression and Cox models.
Results
Among 103 patients with 128 SABR-treated lesions, 72 patients (90 lesions) received SABR+TKI and 31 patients (38 lesions) received SABR+ICI. Acute AEs occurred only in the SABR+TKI group (8.9%), predominantly grade 1. Grade 3 late AEs were rare, occurring in one case in each group, while late AEs of lower grades were more frequent with SABR+ICI (any-grade: 57.9% vs. 25.6%, p<0.001; grade ≥2: 23.7% vs. 8.9%, p=0.024). Multivariable analysis showed borderline increased risk of grade ≥2 late AEs with SABR+ICI (p=0.052). One-year local control, progression-free survival, and overall survival were 76.6%, 35.3%, and 72.3% respectively, with no significant differences between groups.
Conclusion
Metastasis-directed SABR combined with either TKIs or ICIs was generally well tolerated in patients with extrahepatic metastatic HCC, with rare grade 3 late AEs; grade ≥2 late AEs were more frequent with SABR plus ICIs, warranting prospective evaluation.

607 View
50 Download

Circulating Tumor Cell-based Molecular Responses Stratify EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Cancer: Seoyoung Lee, Chaeyeon Kim, Chang Gon Kim, Min Hee Hong, Mina Han, Wonrak Son, Gamin Kim, Hyeong Jung Woo, Hyun Young Shin, Jungmin Lee, Minseok S Kim, Hye Ryun Kim; Received June 29, 2025 Accepted January 26, 2026 Published online January 27, 2026; DOI: https://doi.org/10.4143/crt.2025.672 [Accepted]

Abstract PDF: Purpose
Circulating tumor cell (CTC) is a promising minimally invasive biomarker for EGFR-mutant non-small cell lung cancer (NSCLC). However, the rarity of CTCs and limitations in their isolation and molecular characterization hinder their clinical utility, particularly in predicting treatment outcomes. This study evaluates the potential of CTC molecular response to predict treatment efficacy and guide therapy in patients with EGFR-mutant NSCLC undergoing EGFR-tyrosine kinase inhibitors (TKI) therapy.
Materials and Methods
Seventy-seven patients with EGFR-mutant NSCLC treated with EGFR-TKIs were enrolled. CTCs were isolated using continuous centrifugal microfluidic technology (CCM-CTCD) and compared with ctDNA and tissue biopsy for EGFR mutation analysis. Patients were categorized as CTC molecular responders or non-responders based on a ≥ 44.4% reduction in CTC count from baseline. Progression-free survival (PFS) and tumor burden changes were evaluated.
Results
CTC responders had significantly longer PFS (46.3 vs. 13.6 months, p=0.007) and greater tumor burden reduction (-37.7% vs. -35.2%, p=0.218) compared to non-responders. The CCM-CTCD demonstrated concordance with the cobas test while exhibiting higher sensitivity for EGFR mutation detection among 46 patients who underwent both tests simultaneously. Mutational discordance among tissue, ctDNA, and CTCs highlighted tumor heterogeneity. CTC profiling complemented traditional methods for identifying genomic alterations and predicting early progression.
Conclusion
CTC analysis using CCM-CTCD shows potential as a biomarker for predicting treatment response and prognosis in EGFR-mutant NSCLC. Stratification by CTC molecular response may inform risk-adapted treatment; however, its clinical utility remains to be established. Prospective studies are warranted to validate these findings and determine the role of CTC-guided decision-making.

695 View
74 Download

Genomic Insights into Innate Resistance in Early-Stage EGFR-Mutant Non-Small Cell Lung Cancer: A Comprehensive Analysis of Next-Generation Sequencing Data: Hayoung Seong, Soo Han Kim, Mi-Hyun Kim, Ahrong Kim, Ju Sun Song, Jung Seop Eom; Received January 28, 2025 Accepted August 19, 2025 Published online August 25, 2025; DOI: https://doi.org/10.4143/crt.2025.114 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub: Purpose
Comprehensive genomic profiling of early-stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations remains limited. This study aimed to investigate genomic profiles of early- and advanced-stage EGFR-mutant NSCLC and identify potential innate resistance mechanisms to EGFR-tyrosine kinase inhibitors (TKIs) using targeted next-generation sequencing (NGS).
Materials and Methods
This retrospective observational study analyzed genomic profiles of patients with early-stage (IA-IIIA) and advanced-stage (IIIB-IV) EGFR-mutant NSCLC from the Lung Cancer NGS registry. Targeted NGS was performed to assess concurrent genetic alterations (GAs), tumor mutational burden (TMB), and variant allele frequency (VAF) of EGFR mutations.
Results
Overall, 160 patients (100 early-stage and 60 advanced-stage) were analyzed. The proportion of patients with concurrent GAs was not significantly different between stages (82.0% vs. 91.7%, p=0.092). Median TMB was 3.8 mutations/Mb in both stages, with no significant difference (p=0.206). However, the median VAF of EGFR mutations was significantly lower in early-stage compared to that in advanced-stage (19.3% vs. 29.6%, p=0.002). While TMB remained unchanged with disease progression (p=0.192), VAF of EGFR mutations increased significantly (p < 0.001). Moreover, the frequencies of concurrent single nucleotide variants and copy number variants were significantly lower in early-stage NSCLC.
Conclusion
Genomic heterogeneity in EGFR-mutant NSCLC arises early in tumorigenesis. The comparable TMB and lower VAF of EGFR mutations in early-stage disease suggest that innate resistance to EGFR-TKIs may be driven by concurrent GAs, supporting the consideration of combination therapies even in early-stage EGFR-mutant NSCLC.

1,153 View
80 Download

Preferential Sensitivity of the EGFR L858M/L861R Mutation to Second-Generation EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer: Chaelin Lee, Sheehyun Kim, Soyeon Kim, Taekeun Park, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Jeonghwan Youk; Received March 11, 2025 Accepted August 19, 2025 Published online August 20, 2025; DOI: https://doi.org/10.4143/crt.2025.279 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub

Purpose
Non–small cell lung cancer (NSCLC) frequently harbors targetable epidermal growth factor receptor (EGFR) mutations. However, rare variants such as EGFR L858M or L861R remain poorly characterized. This study aimed to elucidate the oncogenic potential and EGFR tyrosine kinase inhibitors (TKIs) sensitivity of the EGFR L858M/L861R mutation to inform personalized treatment strategies.
Materials and Methods
Tumor samples from an NSCLC patient were analyzed using targeted panel sequencing and confirmed with the FoundationOne Liquid CDx assay. EGFR-mutant constructs, including L858M, L858R, L861R, L861Q, L858M/L861R, and L858R/L861Q, were generated and transduced into various cell lines. Cell viability, immunoblot, and soft agar colony formation assays were conducted to assess the oncogenicity and drug sensitivity, while computational protein modeling and docking simulations evaluated the drug-binding affinities of EGFR-TKIs.
Results
Ba/F3 cells expressing the EGFR L858M/L861R mutation exhibited robust interleukin-3–independent proliferation accompanied by markedly increased EGFR phosphorylation, while NIH-3T3 cells showed anchorage-independent colony formation. Compared to other mutations, cells expressing EGFR L858M/L861R mutation were less sensitive to first-generation EGFR-TKIs (gefitinib, erlotinib) and third-generation EGFR-TKIs (osimertinib, lazertinib), whereas second-generation EGFR-TKIs (afatinib, poziotinib) demonstrated potent inhibitory effects. Computational modeling revealed a narrower drug-binding efficiency of first-generation inhibitors.
Conclusion
The EGFR L858M/L861R mutation drives strong oncogenic signaling and exhibits preferential sensitivity to second-generation EGFR-TKIs. These findings underscore the importance of accurate molecular diagnosis for guiding effective, personalized therapeutic strategies in NSCLC.

Citations

Citations to this article as recorded by

Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy
Jorge J. Nieva, Xuejun Wang, Deborah Doroshow, Leslie Servidio, Miranda Cooper, Yan Kwan Lau, Pritesh S. Karia, Jacqulyne Robichaux
Oncology and Therapy.2026; 14(1): 225. CrossRef

2,099 View
145 Download
1 Crossref

Pediatric cancer

Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric and Young Adult Patients with Chronic Myeloid Leukemia in Tyrosine Kinase Inhibitor Era: A Study of the Korean Blood and Marrow Transplantation Registry: Hee Young Ju, Hyoung Soo Choi, Hyeon Jin Park, Keon Hee Yoo, Chuhl Joo Lyu, Ho Joon Im, Min Kyoung Kim, Yeung-Chul Mun, Joon Ho Moon, Sung-Soo Yoon, Eunyoung Lee, Jae Hoon Lee, Je-Hwan Lee, So Young Chong, June-Won Cheong, Seunghyun Won, on behalf of the Korean Society of Blood and Marrow Transplantation; Cancer Res Treat. 2026;58(2):632-641. Published online May 7, 2025; DOI: https://doi.org/10.4143/crt.2024.1186

Abstract PDF Supplementary Material PubReader ePub: Purpose
Chronic myeloid leukemia (CML) in children, adolescents, and young adults is rare and differs from older adults. This study evaluated the outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) in young Korean CML patients during the tyrosine kinase inhibitor (TKI) era.
Materials and Methods
A retrospective analysis of 35 CML patients aged < 40 years who underwent allogeneic HSCT from 2009 to 2019 was conducted using Korean Blood and Marrow Transplantation Registry data. Patients were grouped by age < 20 years at HSCT (group 1, n=15) and 20-40 years at HSCT (group 2, n=20). Survival outcomes including overall survival (OS), relapse-free survival (RFS), and event-free survival (EFS) were analyzed using the Kaplan-Meier method.
Results
The median time between diagnosis and HSCT was 8.9 months. All the patients achieved engraftment but platelet recovery was significantly slower in group 1 (p=0.034). Acute and chronic graft-versus-host disease occurred in 54.3% and 34.3%, respectively. Five-year OS, RFS, and EFS rates of total patients were 66.8%, 50.8%, and 47.6%, with better OS was observed in group 1 by multivariable analysis (p=0.048). Disease status at HSCT was a significant predictor of OS (p=0.028), RFS (p=0.003), and EFS (p=0.004). Disease progression occurred in 13 out of 35 patients (37.1%); treatment-related mortality accounted for 63.6% of deaths (7 out of 11).
Conclusion
When performed at a younger age, allogeneic HSCT result in superior outcome in CML. Achieving remission before HSCT is critical for improved outcomes, highlighting the importance of pretransplant remission via optimal TKI strategies and minimal residual disease monitoring.

2,111 View
112 Download

Gastrointestinal cancer

Efficacy of Lenvatinib Combined with Anti–PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective, Multicenter Study: Xiangye Ou, Junyi Wu, Jiayi Wu, Yangkai Fu, Zhenxin Zeng, Shuqun Li, Yinan Li, Deyi Liu, Han Li, Bin Li, Jianyin Zhou, Shaowu Zhuang, Shuqun Cheng, Zhibo Zhang, Kai Wang, Shuang Qu, Maolin Yan; Cancer Res Treat. 2024;56(4):1207-1218. Published online April 30, 2024; DOI: https://doi.org/10.4143/crt.2023.1165

Abstract PDF Supplementary Material PubReader ePub

Purpose
The prognosis of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) is extremely poor, and systemic therapy is currently the mainstream treatment. This study aimed to assess the efficacy and safety of lenvatinib combined with anti–programmed cell death-1 antibodies and transcatheter arterial chemoembolization (triple therapy) in patients with HCC and PVTT.
Materials and Methods
This retrospective multicenter study included patients with HCC and PVTT who received triple therapy, were aged between 18 and 75 years, classified as Child-Pugh class A or B, and had at least one measurable lesion. The overall survival (OS), progression-free survival (PFS), objective response rates, and disease control rates were analyzed to assess efficacy. Treatment-related adverse events were analyzed to assess safety profiles.
Results
During a median follow-up of 11.23 months (range, 3.07 to 34.37 months), the median OS was greater than 24 months, and median PFS was 12.53 months. The 2-year OS rate was 54.9%. The objective response rate and disease control rate were 69.8% (74/106) and 84.0% (89/106), respectively; 20.8% (22/106) of the patients experienced grade 3/4 treatment-related adverse events and no treatment-related deaths occurred. The conversion rate to liver resection was 31.1% (33/106), with manageable postoperative complications. The median OS was not reached in the surgery group, but was 19.08 months in the non-surgery group. The median PFS in the surgery and non-surgery groups were 20.50 and 9.00 months, respectively.
Conclusion
Triple therapy showed promising survival benefits and high response rates in patients with HCC and PVTT, with manageable adverse effects.

Citations

Citations to this article as recorded by

Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus
Bin Zhou, Zihui Ma, Lei Wang, Yue Lu, Xi Cheng, Yabo Jiang, Xubiao Wei, Chongde Lu, Shuqun Cheng, Xingsheng Lu
The Oncologist.2026;[Epub] CrossRef
Immunotherapy in Hepatocellular Carcinoma with Portal Vein Tumour Thrombosis: From Poor Prognosis to Curative-Intent Strategies
Luca Marzi, Rodolfo Sacco, Luisa Siciliani, Saveria Lory Crocè, Mauro Giuffrè, Cristina Stasi, Chiara Turri, Monica Zoeschg, Andrea Mega
Cancers.2026; 18(4): 627. CrossRef
Repurposed Acarbose Targets Nidogen-1 to Remodel the Tumor Stroma and Suppress Portal Vein Tumor Thrombus in Hepatocellular Carcinoma
Tao Han, Lujun Chen, Ning Liu, Ying chen Han, Zhi Zhu, Shuyi Wang, Haoran Song, Ziming Gao, Lin Su, Qilin Hu, Linda Hammerich, Timothy M. Pawlik, Yuhan Zhang, Masatoshi Kudo, Hao Li, Lei Ma, Giorgio Valabrega, Guang Wang, Zhengqiang Yang, Qiuhua Luo, Dona
Research.2026;[Epub] CrossRef
Liver resection versus transarterial chemoembolization plus PD-1 inhibitors and lenvatinib for hepatocellular carcinoma with portal vein tumour thrombus
Bin Guo, Shaliheng Yerken, Chu Luo, Zhicheng Liu, Shenjie Xie, Yang Wu, Yongyi Zeng, Hui Zhang, Changzhen Shang, Guandou Yuan, Enyu Liu, Fan Zhang, Wanguang Zhang
BJS Open.2026;[Epub] CrossRef
The efficacy of sequential radiotherapy after the combination of TACE with lenvatinib and anti-PD-1 antibodies for unresectable HCC
Xiangye Ou, Jinhai Li, Rongjian Pan, Deyi Liu, Jiayi Wu, Dong Liang, Yinan Li, Zhenxin Zeng, Han Li, Yuxuan Zhang, Junyi Wu, Maolin Yan
The Oncologist.2026;[Epub] CrossRef
A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma with esophagogastric varices after progression on first-line lenvatinib combined with PD-1 inhibitor
Saifeng Li, Qin Wen, Wenwu Huang, Zeyu Qiu, Long Feng, Fengming Yi
World Journal of Surgical Oncology.2025;[Epub] CrossRef
Personalized prognosis in unresectable hepatocellular carcinoma: Development and validation of a model for transcatheter arterial chemoembolization plus lenvatinib
Jia-Hui Yu, Jun Yu, Jin-Xin Yu, Lin-Feng Yang, Duan Yan, Yi Liu, Ju-Rui Xian, Peng-Sheng Yi
World Journal of Gastrointestinal Oncology.2025;[Epub] CrossRef
Safety and efficacy of salvage surgery for unresectable hepatocellular carcinoma after conversion with triple therapy: a systematic review and meta-analysis of data from Chinese patients
Qingqing Pang, Xingling Mo, Zhihong Tang, Meng Wei, Danxi Liu, Zenghua Zhou, Baishan Huang, Tao Bai, Xiaobo Wang, Feixiang Wu
World Journal of Surgical Oncology.2025;[Epub] CrossRef
Locoregional therapy combined with targeted therapy and immunotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis
Mengjie Jiang, Chao Chen, Yujie Hu, Gang Lin, Huafeng Li
Scientific Reports.2025;[Epub] CrossRef
The effectiveness and safety of immune checkpoint inhibitors in conversion or neoadjuvant therapy for hepatocellular carcinoma: a meta-analysis and systematic review
Lingbo Hu, Yongfu Xu, Yingli Qiao, Aidong Wang, Caidi He, Rongrong Wang
BMC Cancer.2025;[Epub] CrossRef

6,131 View
139 Download
9 Web of Science
10 Crossref

Head and Neck cancer

Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials: Youjin Kim, Bhumsuk Keam, Eun Joo Kang, Jin-Soo Kim, Hye Ryun Kim, Keun-Wook Lee, Jung Hye Kwon, Kyoung Eun Lee, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, Moon Young Choi, Ki Hyeong Lee, Sung-Bae Kim, Myung-Ju Ahn; Cancer Res Treat. 2024;56(4):1068-1076. Published online April 15, 2024; DOI: https://doi.org/10.4143/crt.2024.008

Abstract PDF Supplementary Material PubReader ePub: Purpose
In this study, we evaluated 66 patients diagnosed with adenoid cystic carcinoma (ACC) enrolled in two Korean Cancer Study Group trials to investigate the response and progression patterns in recurrent and/or metastatic ACC treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs).
Materials and Methods
We evaluated 66 patients diagnosed with ACC who were enrolled in the Korean Cancer Study Group trials. The tumor measurements, clinical data, treatment outcomes, and progression patterns of therapy were analyzed.
Results
In the 66 patients (53 receiving axitinib and 13 receiving nintedanib), the disease control rate was 61%, and three patients achieved partial response. The median follow-up, median progression-free survival (PFS), overall survival, and 6-month PFS rate were 27.6%, 12.4%, and 18.1% months and 62.1%, respectively. Among 42 patients who experienced progression, 27 (64.3%) showed target lesion progression. Bone metastasis was an independent poor prognostic factor.
Conclusion
Overall, most patients demonstrated stable disease with prolonged PFS; however, prominent target lesion progression occurred in some patients. Thus, PFS may capture VEGFR-TKI efficacy better than the objective response rate.

4,188 View
174 Download

Lung and Thoracic cancer

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study: Weiguang Gu, Hua Zhang, Yiyu Lu, Minjing Li, Shuang Yang, Jianmiao Liang, Zhijian Ye, Zhihua Li, Minhong He, Xiaoliang Shi, Fei Wang, Dong You, Weiquan Gu, Weineng Feng; Cancer Res Treat. 2023;55(3):841-850. Published online February 13, 2023; DOI: https://doi.org/10.4143/crt.2022.1438

Abstract PDF Supplementary Material PubReader ePub

Purpose
We aimed to evaluate whether the addition of pemetrexed is effective in improving progression-free survival (PFS) in epidermal growth factor receptor (EGFR)–mutated patients with or without concomitant alterations.
Materials and Methods
This multicenter clinical trial was conducted in China from June 15, 2018, to May 31, 2019. A total of 92 non–small cell lung cancer (NSCLC) patients harboring EGFR-sensitive mutations were included and divided into concomitant and non-concomitant groups. Patients in each group were randomly treated with EGFR–tyrosine kinase inhibitor (TKI) monotherapy or EGFR-TKI combined with pemetrexed in a ratio of 1:1. PFS was recorded as the primary endpoint.
Results
The overall median PFS of this cohort was 10.1 months. There were no significant differences in PFS between patients with and without concomitant and between patients received TKI monotherapy and TKI combined with pemetrexed (p=0.210 and p=0.085, respectively). Stratification analysis indicated that patients received TKI monotherapy had a significantly longer PFS in non-concomitant group than that in concomitant group (p=0.002). In concomitant group, patients received TKI combined with pemetrexed had a significantly longer PFS than patients received TKI monotherapy (p=0.013). Molecular dynamic analysis showed rapidly emerging EGFR T790M in patients received TKI monotherapy. EGFR mutation abundance decreased in patients received TKI combined chemotherapy, which supports better efficacy for a TKI combined chemotherapy as compared to TKI monotherapy. A good correlation between therapeutic efficacy and a change in circulating tumor DNA (ctDNA) status was found in 66% of patients, supporting the guiding role of ctDNA minimal residual disease (MRD) in NSCLC treatment.
Conclusion
EGFR-TKI monotherapy is applicable to EGFR-sensitive patients without concomitant alterations, while a TKI combined chemotherapy is applicable to EGFR-sensitive patients with concomitant alterations. CtDNA MRD may be a potential biomarker for predicting therapeutic efficacy.

Citations

Citations to this article as recorded by

Furmonertinib plus pemetrexed in the treatment of EGFR exon 19 deletion lung adenocarcinoma: two case reports
Yuan Zhang, Duofang Wang, Huaxiu Ma, Xiaojun Wang
Frontiers in Oncology.2026;[Epub] CrossRef
Tyrosine kinase inhibitor toxicity in the treatment of non-small-cell lung cancer: A bibliometric analysis (2009–2025)
Lazzat Balymbetova, Yerbolat Maratovich Iztleuov, Elnara Kereevna Ismagulova, Sarkyt Kozhantayeva, Aigerim Balapasheva
Medicine.2026; 105(9): e47860. CrossRef
Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs
Linwu Kuang, Yuchen Zhang, Hao Wang, Peng Wang, Yangkai Li
BMC Pulmonary Medicine.2025;[Epub] CrossRef
Comparison of the Efficacy of Different First‐Line Therapies for EGFR L858R‐Mutated NSCLC Patients With Brain Metastases
Jing Chen, Yin Pan, Baishen Zhang, Meichen Li, Hui Yu, Mingjie Yu, Likun Chen
Cancer Science.2025; 116(11): 3125. CrossRef
SP3-induced Timeless transcription contributes to cell growth of lung adenocarcinoma cells
Ping Tian, Dajun Du, Li Yang, Nan Zhou, Ling Tao, Divijendra Natha Reddy Sirigiri
PLOS ONE.2024; 19(2): e0298295. CrossRef
PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities
Xiaohong Liu, Wuxuan Mei, Pengfei Zhang, Changchun Zeng
Pharmacological Research.2024; 202: 107123. CrossRef
Risk factors for interstitial lung disease in patients with non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors: A systematic review and meta-analysis
Yosuke Fukuda, Yoshitaka Uchida, Koichi Ando, Ryo Manabe, Akihiko Tanaka, Hironori Sagara
Respiratory Investigation.2024; 62(3): 481. CrossRef
Concomitant genomic features stratify prognosis to patients with advanced EGFR mutant lung cancer
Xiao Liang, Jiali Xu, Yuqin Jiang, Yuqian Yan, Hongshuai Wu, Jiali Dai, Yanan Cui, Chen Zhang, Wei Chen, Zhihong Zhang, Renhua Guo
Molecular Carcinogenesis.2024; 63(9): 1643. CrossRef
Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review
Juan Carlos Restrepo, Darly Martínez Guevara, Andrés Pareja López, John Fernando Montenegro Palacios, Yamil Liscano
Cancers.2024; 16(13): 2338. CrossRef

7,676 View
285 Download
8 Web of Science
9 Crossref

Hematologic malignancy

Clinical Impact of Drug Adherence of Tyrosine Kinase Inhibitors in Children with Ph-Positive Acute Lymphoblastic Leukemia: Jun-Xia Wang, Miao-Miao Yang, Li-Peng Liu, Hui-Min Zhang, Meng-Chuan Wang, Yu-Wen Chen, Xiao-Ying Zang, Fang Hu; Cancer Res Treat. 2023;55(3):1023-1030. Published online February 6, 2023; DOI: https://doi.org/10.4143/crt.2022.1618

Abstract PDF PubReader ePub: Purpose
This study aimed to explore the impact of ABL1–tyrosine kinase inhibitors (TKIs) adherence on the survival of chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) children and clarify the potential predictors of patients’ prognosis from TKIs intake practices.
Materials and Methods
Ninety newly diagnosed Ph+ ALL patients who received TKIs were enrolled. We collected the baseline characteristics and adverse events in all children; moreover, TKIs adherence was measured by an eight-item Morisky medication adherence scale (MMAS-8). Progression-free survival (PFS) and overall survival (OS) analysis were performed, and risk factors for PFS and OS were evaluated.
Results
Among all patients, 69 cases were regarded as adherers, while 21 were non-adherers. The median duration of TKIs interruption was significantly prolonged in the non-adherence group than in the adherence group (13 [0-101] vs. 56 [11-128], p < 0.001). Additionally, dose reduction occurred in 55.2% of non-adherers versus 23.0% of adherers (p=0.002). The PFS and OS in adherers were significantly higher versus non-adherers (p=0.020 and p=0.039). MMAS-8 score was an independent risk factor for PFS (p=0.010) and OS (p=0.031). Among non-adherers, the median OS was only 23.1% (4.2%-42%) in patients aged ≤ 10 years versus 54.4% (38.8%-70%) in adolescents. Most of the patients who experienced TKIs non-adherence suffered pancytopenia.
Conclusion
TKIs adherence during treatment significantly influenced the survival of pediatric Ph+ ALL patients, and non-adherers with age ≤ 10 years were more vulnerable to TKIs disruption. The cumulative TKIs dose should be especially emphasized to patients with age ≤ 10 years, which may result in an inferior achievement of relevant treatment milestones.

4,770 View
151 Download

Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma: In Kyoung Hwang, Seung Sook Paik, Seung Hyeun Lee; Cancer Res Treat. 2019;51(1):158-168. Published online April 2, 2018; DOI: https://doi.org/10.4143/crt.2018.084

Abstract PDF Supplementary Material PubReader ePub

Purpose
Although it has been suggested that pulmonary tuberculosis (TB) is associated with increased risk of lung cancer, the exact mechanism is not clearly identified. We investigated the effect of pulmonary TB on the epidermal growth factor receptor (EGFR) mutational status and clinical outcome in patients with pulmonary adenocarcinoma.
Materials and Methods
We reviewed data of patients diagnosed with pulmonary adenocarcinoma harboring EGFR mutations and treated at our institution from 2008 to 2015. We divided our population into two groups: patients with pre-existing TB lesions on chest computed tomography scan (TB group) and those without the lesions (non-TB group). We compared the differences in EGFR mutational status, response to tyrosine kinase inhibitors (TKIs) and survival between the two groups.
Results
A total of 477 patients with pulmonary adenocarcinoma were analyzed. One hundred eighty-three patients (39%) had EGFR-mutated tumors and 100 (21%) patients had pre-existing TB lesions. The frequency of EGFR mutation was significantly higher in the TB group compared with the non-TB group (56% vs. 34%, p=0.038). Pre-existing TB lesions were independently associated with more frequent EGFR mutations in multivariate analysis (odds ratio, 1.43). In addition, both the progression-free survival (9.1 months vs. 11.6 months, p=0.020) and the overall survival (19.4 months vs. 24.5 months, p=0.014) after first-line EGFR-TKIs were significantly shorter in the TB group than in the non-TB group.
Conclusion
Previous pulmonary TB may be associated with more frequent EGFR mutations and poorer treatment response to EGFR-TKIs in patients with pulmonary adenocarcinoma.

Citations

Citations to this article as recorded by

A DNA Methylation Signature From Buccal Swabs to Identify Tuberculosis Infection
Lovisa Karlsson, Isabelle Öhrnberg, Shumaila Sayyab, David Martínez-Enguita, Mika Gustafsson, Patricia Espinoza, Melissa Méndez-Aranda, Cesar Ugarte-Gil, Lameck Diero, Ronald Tonui, Jakob Paues, Maria Lerm
The Journal of Infectious Diseases.2025; 231(1): e47. CrossRef
Contagious illness of tuberculosis and correlation with various types of cancer
Karthikeyan Sundaram, Venkataraman Prabhu
Medicine in Microecology.2025; 24: 100123. CrossRef
Coexistent Pulmonary Tuberculosis and Lung Cancer: An Analysis of Incidence Trends, Financial Burdens and Influencing Factors
Fei Qi, Hongjie Yang, Yi Han, Yujie Dong, Fan Zhang, Yishuo Wang, Juan Du, Yuan Gao, Xueguang Hu, Liqun Zhang, Tongmei Zhang
Cancer Innovation.2025;[Epub] CrossRef
Coexisting Lung Cancer and Pulmonary Tuberculosis: A Comprehensive Review From Incidence to Management
Wendi Zhou, Hongxu Lu, Jiamin Lin, Jialou Zhu, Jizhen Liang, Yalin Xie, Jinxing Hu, Ning Su
Cancer Reports.2025;[Epub] CrossRef
New Vistas in Mycobacterium tuberculosis Infection and Its Association with Lung Cancer Development
Kostas A. Papavassiliou, Amalia A. Sofianidi, Fotios G. Spiliopoulos, Alice G. Vassiliou, Athanasios G. Papavassiliou
Cancers.2025; 17(13): 2224. CrossRef
Real-world progression-free survival of first line afatinib patients with EGFR-mutant advanced lung adenocarcinoma: A multicentre study in Indonesia
Noni Novisari Soeroso, Elisna Syahruddin, Chaliza Soliha, Laksmi Wulandari, Ana Rima Setijadi, Sabrina Ermayanti, Suryanti Dwi Pratiwi, Andreas Infianto, Novita Andayani, Sri Melati Munir, Avissena Dutha Pratama, Ida Ayu Jasminarti Dwi Kusumawardani, Hary
Cancer Treatment and Research Communications.2025; 44: 100979. CrossRef
Tuberculosis Coinciding With Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma: A Diagnostic Conundrum
Nithiyanandan Ravi
Cureus.2025;[Epub] CrossRef
Reprogramming the host: Mycobacterium tuberculosis as a silent architect of the immuno-tumoral
Rodolfo L. Chávez-Domínguez, Martha Torres, Atziri A. Acevedo-Domínguez, Jesús A. Ibarra-Inocente, Claudia Carranza
Frontiers in Cellular and Infection Microbiology.2025;[Epub] CrossRef
Progress in mechanism-based diagnosis and treatment of tuberculosis comorbid with tumor
Chuan Wang, Rong-Qi Zou, Guo-Zhong He
Frontiers in Immunology.2024;[Epub] CrossRef
Lung cancer and pulmonary tuberculosis: key features of molecular mechanisms of concomitant disease
G. M. Agafonov, G. G. Kudriashov, U. S. Krylova, T. S. Zubareva, I. M. Kvetnoy, P. K. Yablonskiy
Uspehi fiziologičeskih nauk.2024; 55(3): 58. CrossRef
Antimicrobial peptides as drugs with double response against Mycobacterium tuberculosis coinfections in lung cancer
Giulia Polinário, Laura Maria Duran Gleriani Primo, Maiara Alane Baraldi Cerquetani Rosa, Freddy Humberto Marin Dett, Paula Aboud Barbugli, Cesar Augusto Roque-Borda, Fernando Rogério Pavan
Frontiers in Microbiology.2023;[Epub] CrossRef
Mycobacterium Tubercular Mediated Inflammation and Lung Carcinogenesis: Connecting Links
Abhay Vashishth, Mohd Shuaib, Tanya Bansal, Shashank Kumar
OBM Genetics.2023; 07(02): 1. CrossRef
Prevalence of Lung Cancer with a History of Tuberculosis
Nadira Putri Nastiti, Laksmi Wulandari, Sulistiawati Sulistiawati, Anna Febriani, Wiwin Is Effendi
Jurnal Respirasi.2023; 9(2): 87. CrossRef
Previous pulmonary tuberculosis enhances the risk of lung cancer: systematic reviews and meta-analysis
Hossein Abdeahad, Maryam Salehi, Atieh Yaghoubi, Amir Hossein Aalami, Farnoosh Aalami, Saman Soleimanpour
Infectious Diseases.2022; 54(4): 255. CrossRef
Pulmonary Tuberculosis and Risk of Lung Cancer: A Systematic Review and Meta-Analysis
Soo Young Hwang, Jong Yeob Kim, Hye Sun Lee, Sujee Lee, Dayeong Kim, Subin Kim, Jong Hoon Hyun, Jae Il Shin, Kyoung Hwa Lee, Sang Hoon Han, Young Goo Song
Journal of Clinical Medicine.2022; 11(3): 765. CrossRef
Clinical and pathological characteristics associated with the presence of the IS6110 Mycobacterim tuberculosis transposon in neoplastic cells from non-small cell lung cancer patients
Oscar Arrieta, Camilo Molina-Romero, Fernanda Cornejo-Granados, Brenda Marquina-Castillo, Alejandro Avilés-Salas, Gamaliel López-Leal, Andrés F. Cardona, Alette Ortega-Gómez, Mario Orozco-Morales, Adrián Ochoa-Leyva, Rogelio Hernandez-Pando
Scientific Reports.2022;[Epub] CrossRef
Lung cancer occurrence after an episode of tuberculosis: a systematic review and meta-analysis
Javier Cabrera-Sanchez, Vicente Cuba, Victor Vega, Patrick Van der Stuyft, Larissa Otero
European Respiratory Review.2022; 31(165): 220025. CrossRef
Proteomic profile of vitreous in patients with tubercular uveitis
Reema Bansal, Mohd M. Khan, Surendra Dasari, Indu Verma, David R. Goodlett, Nathan P. Manes, Aleksandra Nita-Lazar, Surya P. Sharma, Aman Kumar, Nirbhai Singh, Anuradha Chakraborti, Vishali Gupta, M.R. Dogra, Jagat Ram, Amod Gupta
Tuberculosis.2021; 126: 102036. CrossRef
Epidermal growth factor receptor-mutant pulmonary adenocarcinoma coexisting with tuberculosis
Ning Liu, Lingnan Zheng, Min Yu, Shuang Zhang
Medicine.2021; 100(8): e24569. CrossRef
Quantitative analysis of cell-free DNA by droplet digital PCR reveals the presence of EGFR mutations in non-malignant lung pathologies
Rajesh Venkataram, Srividya Arjuna, Giridhar Belur Hosmane, Anirban Chakraborty
Monaldi Archives for Chest Disease.2021;[Epub] CrossRef
Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
Yalin Xie, Ning Su, Wei Zhou, An Lei, Xiang Li, Weiwei Li, Zhan Huang, Wenchang Cen, Jinxing Hu
Cancer Management and Research.2021; Volume 13: 7517. CrossRef
A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient
Caibao Jin, Bin Yang
Case Reports in Oncology.2021; 14(1): 659. CrossRef
Follow‐up of an occult tuberculosis scar cancer after resection of metastatic lesions
Mengyao Sun, Yinghui Xu, Xu Wang, Chao Sun, Ye Guo, Guoguang Shao, Zhiguang Yang, Yunpeng Liu, Peng Zhang, Shi Qiu, Kewei Ma
Thoracic Cancer.2020; 11(8): 2347. CrossRef

11,896 View
284 Download
20 Web of Science
23 Crossref

Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model: Pawel Chrom, Rafal Stec, Lubomir Bodnar, Cezary Szczylik; Cancer Res Treat. 2018;50(1):103-110. Published online March 3, 2017; DOI: https://doi.org/10.4143/crt.2017.033

Abstract PDF Supplementary Material PubReader ePub

Purpose
The study investigated whether a replacement of neutrophil count and platelet count by neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) within the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model would improve its prognostic accuracy.
Materials and Methods
This retrospective analysis included consecutive patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. The IMDC and modified-IMDC models were compared using: concordance index (CI), bias-corrected concordance index (BCCI), calibration plots, the Grønnesby and Borgan test, Bayesian Information Criterion (BIC), generalized R², Integrated Discrimination Improvement (IDI), and continuous Net Reclassification Index (cNRI) for individual risk factors and the three risk groups.
Results
Three hundred and twenty-one patients were eligible for analyses. The modified-IMDC model with NLR value of 3.6 and PLR value of 157 was selected for comparison with the IMDC model. Both models were well calibrated. All other measures favoured the modified-IMDC model over the IMDC model (CI, 0.706 vs. 0.677; BCCI, 0.699 vs. 0.671; BIC, 2,176.2 vs. 2,190.7; generalized R², 0.238 vs. 0.202; IDI, 0.044; cNRI, 0.279 for individual risk factors; and CI, 0.669 vs. 0.641; BCCI, 0.669 vs. 0.641; BIC, 2,183.2 vs. 2,198.1; generalized R², 0.163 vs. 0.123; IDI, 0.045; cNRI, 0.165 for the three risk groups).
Conclusion
Incorporation of NLR and PLR in place of neutrophil count and platelet count improved prognostic accuracy of the IMDC model. These findings require external validation before introducing into clinical practice.

Citations

Citations to this article as recorded by

Correlation of Prognostic Nutritional Index and Systemic Immune-Inflammation Index with the Recurrence and Prognosis in Oral Squamous Cell Carcinoma with the Stage of III/IV
Manjun Ye, Lixia Zhang
International Journal of General Medicine.2024; Volume 17: 2289. CrossRef
Evaluating the Prognostic Variables for Overall Survival in Patients with Metastatic Renal Cell Carcinoma: A Meta-Analysis Of 29,366 Patients
Bruce Li, Swati Sood, Melissa J. Huynh, Nicholas E. Power
JU Open Plus.2024;[Epub] CrossRef
The relationship between complete blood cell count-derived inflammatory biomarkers and benign prostatic hyperplasia in middle-aged and elderly individuals in the United States: Evidence from NHANES 2001–2008
Chengdong Shi, Hongliang Cao, Guoqiang Zeng, Lei Yang, Yuantao Wang, Alaa A. A. Aljabali
PLOS ONE.2024; 19(7): e0306860. CrossRef
Evaluation of prognostic factors for late recurrence in clear cell renal carcinoma: an institutional study
Diana Voskuil-Galoş, Tudor Călinici, Andra Piciu, Adina Nemeş
Frontiers in Oncology.2024;[Epub] CrossRef
Plasma carnitine, choline, γ-butyrobetaine, and trimethylamine-N-oxide, but not zonulin, are reduced in overweight/obese patients with pre/diabetes or impaired glycemia
Alia Snouper, Violet Kasabri, Nailya Bulatova, Maysa Suyagh, Monther Sadder, Khaldoun Shnewer, Ismail Yousef
International Journal of Diabetes in Developing Countries.2023; 43(4): 592. CrossRef
Artificial intelligence-based prediction of overall survival in metastatic renal cell carcinoma
Ella Barkan, Camillo Porta, Simona Rabinovici-Cohen, Valentina Tibollo, Silvana Quaglini, Mimma Rizzo
Frontiers in Oncology.2023;[Epub] CrossRef
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Small Renal Cell Carcinomas after Image-Guided Cryoablation or Radio-Frequency Ablation
Aqua Asif, Vinson Wai-Shun Chan, Filzah Hanis Osman, Jasmine Sze-Ern Koe, Alexander Ng, Oliver Edward Burton, Jon Cartledge, Michael Kimuli, Naveen Vasudev, Christy Ralph, Satinder Jagdev, Selina Bhattarai, Jonathan Smith, James Lenton, Tze Min Wah
Cancers.2023; 15(7): 2187. CrossRef
A meta-analysis of the platelet-lymphocyte ratio: A notable prognostic factor in renal cell carcinoma
Xiao Zhou, Guangcheng Luo
The International Journal of Biological Markers.2022; 37(2): 123. CrossRef
Prognostic Role of Systemic Inflammatory Markers in Patients Undergoing Surgical Resection for Oral Squamous Cell Carcinoma
Uiju Cho, Yeoun-Eun Sung, Min-Sik Kim, Youn-Soo Lee
Biomedicines.2022; 10(6): 1268. CrossRef
Prognostic value of glucose to lymphocyte ratio for patients with renal cell carcinoma undergoing laparoscopic nephrectomy: A multi-institutional, propensity score matching cohort study
Jinliang Ni, Ziye Li, Wei Song, Houliang Zhang, Yidi Wang, Yifan Zhang, Haipeng Zhang, Guangcan Yang, Jun Xie, Keyi Wang, Bo Peng, Weipu Mao
Frontiers in Surgery.2022;[Epub] CrossRef
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
Yasser Ged, Alejandro Sanchez, Sujata Patil, Andrea Knezevic, Emily Stein, Stacey Petruzella, Kate Weiss, Cihan Duzgol, Joshua Chaim, Oguz Akin, Marina Mourtzakis, Michael T. Paris, Jessica Scott, Fengshen Kuo, Ritesh Kotecha, A. Ari Hakimi, Chung-Han Lee
Clinical Cancer Research.2022; 28(23): 5180. CrossRef
Exploratory Analysis of the Platelet-to-Lymphocyte Ratio Prognostic Value in the Adjuvant Renal Cell Cancer Setting
Anup Patel, Alain Ravaud, Robert J Motzer, Allan J Pantuck, Michael Staehler, Bernard Escudier, Jean-François Martini, Mariajose Lechuga, Xun Lin, Daniel J George
Future Oncology.2021; 17(4): 403. CrossRef
Preoperative anaemia and thrombocytosis predict adverse prognosis in non‐metastatic renal cell carcinoma with tumour thrombus
Ruotao Xiao, Chuxiao Xu, Wei He, Lei Liu, Hongxian Zhang, Cheng Liu, Lulin Ma
BMC Urology.2021;[Epub] CrossRef
Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma According to Risk Factors: The STAR-TOR Registry
Arne Strauss, Marianne Schmid, Michael Rink, Michael Moran, Stephan Bernhardt, Marcus Hubbe, Lothar Bergmann, Katrin Schlack, Martin Boegemann
Future Oncology.2021; 17(18): 2325. CrossRef
Systemic Inflammation Response Index is an Independent Prognostic Indicator for Patients with Renal Cell Carcinoma Undergoing Laparoscopic Nephrectomy: A Multi-Institutional Cohort Study
Weipu Mao, Si Sun, Ting He, Xin Jin, Jianping Wu, Bin Xu, Guangyuan Zhang, Keyi Wang, Ming Chen
Cancer Management and Research.2021; Volume 13: 6437. CrossRef
Can Systemic Immune-Inflammation Index Create a New Perspective for the IMDC Scoring System in Patients with Metastatic Renal Cell Carcinoma?
Fatma Bugdayci Basal, Cengiz Karacin, Irem Bilgetekin, Omur Berna Oksuzoglu
Urologia Internationalis.2021; 105(7-8): 666. CrossRef
Post-surgical Regression of Thoracic Metastases After Salvage Lobectomy for Recurrent Renal Cell Carcinoma
Alessia Stanzi, Elena Verzoni, Margherita Ruggirello, Luigi Rolli, Ugo Pastorino
Clinical Genitourinary Cancer.2020; 18(3): e284. CrossRef
Peking University Third Hospital score: a comprehensive system to predict intra-operative blood loss in radical nephrectomy and thrombectomy
Zhuo Liu, Xun Zhao, Hong-Xian Zhang, Run-Zhuo Ma, Li-Wei Li, Shi-Ying Tang, Guo-Liang Wang, Shu-Dong Zhang, Shu-Min Wang, Xiao-Jun Tian, Lu-Lin Ma
Chinese Medical Journal.2020; 133(10): 1166. CrossRef
Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma
Guilherme Nader Marta, Pedro Isaacsson Velho, Renata R. C. Bonadio, Mirella Nardo, Sheila F. Faraj, Manoel Carlos L. de Azevedo Souza, David Q. B. Muniz, Diogo Assed Bastos, Carlos Dzik
Pathology & Oncology Research.2020; 26(4): 2489. CrossRef
The Clinical Significance of Routine Risk Categorization in Metastatic Renal Cell Carcinoma and its Impact on Treatment Decision-Making: A Systematic Review
Shouki Bazarbashi, Abdullah Alsharm, Faisal Azam, Hazem El Ashry, Jamal Zekri
Future Oncology.2020; 16(34): 2879. CrossRef
Patient selection and risk factors in the changing treatment landscape of metastatic renal cell carcinoma
Ehab Abdou, Ravi M. Pedapenki, Mohamed Abouagour, Abdul R. Zar, Emad Dawoud, Dalia Elshourbagy, Humaid O. Al-Shamsi, Enrique Grande
Expert Review of Anticancer Therapy.2020; 20(10): 831. CrossRef
Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial
Anup Patel, Alain Ravaud, Robert J. Motzer, Allan J. Pantuck, Michael Staehler, Bernard Escudier, Jean-François Martini, Mariajose Lechuga, Xun Lin, Daniel J. George
Clinical Cancer Research.2020; 26(18): 4863. CrossRef
External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model
Pawel Chrom, Jakub Zolnierek, Lubomir Bodnar, Rafal Stec, Cezary Szczylik
International Journal of Clinical Oncology.2019; 24(5): 526. CrossRef
Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution
Mario Uccello, Tasnim Alam, Haider Abbas, Ajith Nair, Jennifer Paskins, Guy Faust
Clinical Genitourinary Cancer.2019; 17(3): e658. CrossRef
Towards individualized therapy for metastatic renal cell carcinoma
Ritesh R. Kotecha, Robert J. Motzer, Martin H. Voss
Nature Reviews Clinical Oncology.2019; 16(10): 621. CrossRef
The impact of neutrophil-to-lymphocyte, platelet-to-lymphocyte and haemoglobin-to-platelet ratio on localised renal cell carcinoma oncologic outcomes
S. Albisinni, D. Pretot, W. Al Hajj Obeid, F. Aoun, T. Quackels, A. Peltier, T. Roumeguère
Progrès en Urologie.2019; 29(8-9): 423. CrossRef
Prognostic Significance of Systemic Inflammatory Response in Patients with Synchronous and Metachronous Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors
Joongwon Choi, Tae Jin Kim, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Minyong Kang, Seong Il Seo
The Korean Journal of Urological Oncology.2019; 17(3): 150. CrossRef
The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma
Joanna Huszno, Zofia Kolosza, Jolanta Mrochem-Kwarciak, Tomasz Rutkowski, Krzysztof Skladowski
Oncology.2019; 97(1): 7. CrossRef
Platelet-to-lymphocyte ratio in advanced Cancer: Review and meta-analysis
Bo Li, Pingting Zhou, Yujie Liu, Haifeng Wei, Xinghai Yang, Tianrui Chen, Jianru Xiao
Clinica Chimica Acta.2018; 483: 48. CrossRef
Combined neutrophil/platelet/lymphocyte/differentiation score predicts chemosensitivity in advanced gastric cancer
Zhenhua Huang, Yantan Liu, Chen Yang, Xiaoyin Li, Changqie Pan, Jinjun Rao, Nailin Li, Wangjun Liao, Li Lin
BMC Cancer.2018;[Epub] CrossRef
The clinical use of the platelet to lymphocyte ratio and lymphocyte to monocyte ratio as prognostic factors in renal cell carcinoma: a systematic review and meta-analysis
Xuemin Wang, Shiqiang Su, Yuanshan Guo
Oncotarget.2017; 8(48): 84506. CrossRef

14,318 View
214 Download
29 Web of Science
31 Crossref

First
Prev
Page of 1
Next
Last

Search